Next Article in Journal
Assessment of Dynamic Knee Valgus between Lateral Step-Down Test and Running in Female Runners with and without Patellofemoral Pain Using Two-Dimensional Video Analysis
Previous Article in Journal
The Clinical Utility of ABO and RHD Systems as Potential Indicators of Health Status, a Preliminary Study in Greek Population
Case Report

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Georgia Cancer Center, Medical College of Georgia Augusta University, Augusta, GA 30912, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Ulrich Sack
Clin. Pract. 2022, 12(3), 419-424; https://doi.org/10.3390/clinpract12030046
Received: 17 May 2022 / Revised: 7 June 2022 / Accepted: 8 June 2022 / Published: 10 June 2022
Lung cancer is the leading cause of cancer-related deaths. Surgery remains the best option to treat lung cancer when feasible. However, many cases are diagnosed beyond the initial stages. There has been tremendous progress in the treatment of lung cancer over the last few years. Studies have shown that biomarker-driven targeted therapies lead to better outcomes. Due to the technical difficulties and significant procedural risk associated with repeated tissue biopsies, analysis of tumor constituents circulating in the blood, such as circulating tumor DNA (ctDNA) and various proteins, is becoming more widely recognized as an alternative method of tumor sampling, i.e., liquid biopsy. Liquid biopsy is superior to tissue biopsy, as it is minimally invasive and easily repeatable. Given the recent data on changes in mutations as the disease progresses or responds to treatment, liquid biopsies can help monitor the changes and guide us in giving targeted drugs. Here we present a case of advanced NSCLC who was initially started on Alectinib based on positivity for ALK gene rearrangement found in the FISH study. At the time of progression, molecular profiling liquid biopsy was obtained, which revealed KRAS-p.G12C mutation. Thus, the patient’s therapy was later on changed to sotorasib after the FDA approved a KRAS-p.G12C mutation inhibitor. View Full-Text
Keywords: non-small-cell lung cancer (NSCLC); sotorasib; liquid biopsy; mutation non-small-cell lung cancer (NSCLC); sotorasib; liquid biopsy; mutation
Show Figures

Figure 1

MDPI and ACS Style

Sama, S.; Le, T.; Ullah, A.; Elhelf, I.A.; Kavuri, S.K.; Karim, N.A. The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). Clin. Pract. 2022, 12, 419-424. https://doi.org/10.3390/clinpract12030046

AMA Style

Sama S, Le T, Ullah A, Elhelf IA, Kavuri SK, Karim NA. The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinics and Practice. 2022; 12(3):419-424. https://doi.org/10.3390/clinpract12030046

Chicago/Turabian Style

Sama, Srikar, Thuy Le, Asad Ullah, Islam A. Elhelf, Sravan K. Kavuri, and Nagla A. Karim. 2022. "The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)" Clinics and Practice 12, no. 3: 419-424. https://doi.org/10.3390/clinpract12030046

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop